Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF)

Combined chemoradiation and radiofrequency electromagnetic field treatment for patients with glioblastoma

Trial Details

NCT ID
NCT06140875
Phase
NA
Sponsor
Charite University, Berlin, Germany
Status
RECRUITING
Cancer Type
Glioblastoma (GBM) Brain Cancer
Interventions
  • Radiofrequency electromagnetic field treatment
Locations (sample)
  • Berlin, Germany|52.52437,13.41053

Key Eligibility Criteria

  • Pathological evidence of newly diagnosed glioblastoma according to WHO classification criteria
  • Patients 18 to 70 years of age with a WHO performance status of 2 or less
  • All patients must sign written informed consent
  • Adequate hematologic, renal, and hepatic function (absolute neutrophil count, ≥1,5 x 103/μL; platelet count, ≥100 x 103/μL; serum creatinine ≤1.7 m…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →